Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E

Virology
Shixia WangShan Lu

Abstract

A major challenge in developing an HIV-1 vaccine is to identify immunogens and their delivery methods that can elicit broad neutralizing antibodies against primary isolates of different genetic subtypes. Recently, we demonstrated that priming with DNA vaccines expressing primary HIV-1 envelope glycoprotein (Env) followed by recombinant Env protein boosting was successful in generating positive neutralizing antibody responses against a clade B primary HIV-1 isolate, JR-FL, that was not easily neutralized. In the current study, we examined whether the DNA priming plus recombinant protein boosting approach delivering a polyvalent primary Env formulation was able to generate neutralizing antibodies against primary HIV-1 viral isolates from various genetic subtypes. New Zealand White rabbits were first immunized with DNA vaccines expressing one, three or eight primary HIV-1 gp120 antigens delivered by a gene gun followed by recombinant gp120 protein boosting. Neutralizing antibody responses were examined by two independently executed neutralization assays: the first one was a single round infection neutralization assay against a panel of 10 primary HIV-1 isolates of subtypes A, B, C and E and the second one used the PhenoSense assay...Continue Reading

References

Sep 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·K JavaherianS D Putney
Apr 12, 1994·Proceedings of the National Academy of Sciences of the United States of America·A J ConleyE A Emini
Sep 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·W S PearD Baltimore
Dec 1, 1994·AIDS Research and Human Retroviruses·M PurtscherA Jungbauer
Aug 19, 1997·Proceedings of the National Academy of Sciences of the United States of America·N L LetvinJ W Shiver
May 18, 1999·Biochemical and Biophysical Research Communications·R H StauberN I Tarasova
Mar 18, 2000·Antimicrobial Agents and Chemotherapy·C J PetropoulosJ M Whitcomb
Jul 13, 2000·AIDS Research and Human Retroviruses·M BabaK Okonogi
Apr 3, 2001·Science·D Paydarfar, W J Schwartz
Oct 20, 2001·Transfusion clinique et biologique : journal de la Société française de transfusion sanguine·R M RuprechtH M McClure
May 9, 2002·Proceedings of the National Academy of Sciences of the United States of America·Maxime MoulardDimiter S Dimitrov
Jun 29, 2002·Science·Brian GaschenBette Korber
Jul 18, 2002·IUBMB Life·Lynn Morris
Mar 20, 2003·Proceedings of the National Academy of Sciences of the United States of America·Douglas D RichmanChristos J Petropoulos
Mar 21, 2003·Nature·Xiping WeiGeorge M Shaw
Mar 28, 2003·The Journal of Infectious Diseases·Marta-Louise AckersJ Steven McDougal
Nov 25, 2003·Proceedings of the National Academy of Sciences of the United States of America·Yoshiaki NishimuraMalcolm A Martin
Aug 3, 2004·Nature Medicine·John P Moore, Dennis R Burton

❮ Previous
Next ❯

Citations

Jan 1, 2014·Vaccines·Yuxin ChenShan Lu
Jul 25, 2008·Proceedings of the National Academy of Sciences of the United States of America·Sampa SantraNorman L Letvin
May 1, 2007·Current Opinion in HIV and AIDS·David C MontefioriJohn R Mascola
Jul 25, 2009·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Michael VaineShixia Wang
Oct 6, 2006·Springer Seminars in Immunopathology·Shan Lu
Mar 3, 2010·Annual Review of Immunology·John R Mascola, David C Montefiori
Apr 4, 2007·Expert Review of Anti-infective Therapy·Chuen-Yen LauMargaret I Johnston
Nov 5, 2008·Expert Review of Vaccines·Sean P McBurney, Ted M Ross
Aug 28, 2015·Expert Review of Vaccines·Lu ZhangShixia Wang
Aug 3, 2011·Expert Review of Vaccines·Joseph W Golden, Jay W Hooper
May 16, 2012·Expert Opinion on Biological Therapy·Sandhya Vasan, Nelson L Michael
Apr 27, 2010·The Lancet Infectious Diseases·Anna Laura RossLuigi Buonaguro
Jun 9, 2009·Current Opinion in Immunology·Shan Lu
Mar 11, 2008·Biochemical and Biophysical Research Communications·Anthony D CristilloRanajit Pal
Nov 27, 2014·Human Vaccines & Immunotherapeutics·Kristin HollisterAlexander Dent

❮ Previous
Next ❯